Aromatic compounds and their use in medical applications

Details Aromatic compounds and their use in medical applications Aromatic compounds and their use in medical applications

2011-04-12

2011-04-12

Hui, San-ming (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Hydrocarbon doai

C514S715000, C564S305000

Reexamination Certificate

active

07923473

ABSTRACT:
Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrierwherein the symbols have the following meaning—X— is e.g.and Y being e.g.or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

REFERENCES:
patent: 4363813 (1982-12-01), Kawasaki et al.
patent: 5374772 (1994-12-01), Casson et al.
patent: 6248790 (2001-06-01), Uckun et al.
patent: 6432957 (2002-08-01), Kodoma et al.
patent: 2003/0187306 (2003-10-01), Sinha et al.
patent: 2005/0113416 (2005-05-01), Wang et al.
patent: 2008/0249107 (2008-10-01), Kranich et al.
patent: 0217204 (1987-04-01), None
patent: 0465122 (1992-01-01), None
patent: 00426468 (1995-09-01), None
patent: 0840606 (2000-06-01), None
patent: 0758243 (2003-03-01), None
patent: 1481669 (2004-12-01), None
patent: 1577289 (2005-09-01), None
patent: 1627644 (2006-02-01), None
patent: 2003 055369 (2003-06-01), None
patent: WO 97/01569 (1997-01-01), None
patent: WO 99/29705 (1999-06-01), None
patent: WO 99/29705 (1999-06-01), None
patent: WO 99/29706 (1999-06-01), None
patent: WO 99/29706 (1999-06-01), None
patent: WO 00/33836 (2000-06-01), None
patent: WO 97/01335 (2003-01-01), None
patent: WO 03/075905 (2003-09-01), None
patent: WO 03/097658 (2003-11-01), None
patent: WO 03/097658 (2003-11-01), None
patent: WO 2004/018502 (2004-03-01), None
patent: WO 2005/090284 (2005-09-01), None
van De Waterbeemd H, Smith DA, Beaumont K, and Walker DK, “Property-based design: optimization of drug absorption and pharmacokinetics,” Journal of Medicinal Chemistry, Apr. 2001,44(9), 1313-1333.
R.P. McEver, “8 Interactions of Selectins with PSGL-1 and Other Ligands”,Ernst Schering Res. Found. Workshop, 2004, 44, pp. 137-147.
G. Constantin, “PSGL-1 as a Novel Therapeutic Target”, Drug News Perspect 17(9), Nov. 2004, pp. 579-586.
Okazaki et al., “Enhancement of Metastatic Activity of Colon Cancer as influenced by Expression of Cell Surface Antigens”, Journal of Surgical Research , 78, JR985298, pp. 78-84, Sep. 22, 1997.
A.M. Müller et al., “Heterogeneous expression of cell adhesion molecules by endothelial cells in ARDS”, Journal of Pathology, 2002, 198(2), pp. 270-275.
R.P. McEver, “Selectin-carbohydrate interactions during inflammation and metastasis”, Glycoconjugate Journal (1997) 14: 585-591, pp, 585-591.
R.P. McEver et al., “Perspectives Series: Cell Adhesion in Vascular Biology” “Role of PSGL-1 Binding to Selectins in Leukocyte Recruitment”, J. Clin. Invest., The American Society for Clinical Investigation, Inc., vol. 100, No. 3, Aug. 1997, pp. 485-492.
A. Di Stefano et al., “Upregulation of Adhesion Molecules in the Bronchial Mucosa of Subjects with Chronic Obstructive Bronchitis”, Am. J. Respir. Crit. Care. Med., 1994, vol. 149, No. 3, pp. 803-810.
S. Terajima et al., “An important role of tumor necrosis factor-α in the induction of adhesion molecules in psoriasis”, Arch. Dermatol. Res., 1998, 290, pp. 246-252.
M. Sperandio et al., “Blocking Leukocyte Rolling: Does it have a Role in Disease Prevention?”, Vascular Disease Prevention, 2004, 1, pp. 185-195.
C.A. Lipinski et al., “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings”, Advanced Drug Delivery Reviews, 23, 1997, pp. 3-25.
H. Ulbrich et al., “Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease”, Trends in Pharmacological Sciences, 2003, 24(12), pp. 640-647.
S.J. Romano, “Selectin Antagonists, Therapeutic Potential in Asthma and COPD”, Treat. Respir. Med. 2005, 4(2) , pp. 85-94.
M.P. Schön, “Inhibitors of selectin functions in the treatment of inflammatory skin disorders”, Therapeutics and Clinical Risk Management, 2005, 1(3), pp. 201-208.
M. Kumamoto et al., “Effects of pH and Metal Ions on Antioxidative Activities of Catechins”, Biosci. Biotechnol. Biochem., 64 (1), 2001, pp. 126-132.
E. Sergediene et al., “Prooxidant toxicity of polyphenolic antioxidants to HL-60 cells: description of quantitative structure-activity relationships”, FEBS Lettes 462 (1999) 392-396.
K. Satoh et al., “Copper, but not Iron, Enhances Apoptosis-Inducing Activity of Antioxidants”, Anticancer Research 17: (1997), pp. 2487-2490.
N. Sakuguchi et al., “Reactive Oxygen Species and Intracellular Ca2+, Common Signals for Apoptosis Induced by Gallic Acid”, Biochemical Pharmacology, vol. 55, pp. 1973-1981, 1998.
D. Bock et al., Innovative Strategy in Inflammatory Diseases, New Drugs, 2003, D04, 28, pp. 28-30.
E. Aydt et al., “Development of Synthetic Pan-Selectin Antagonists: A New Treatment Strategy for Chronic Inflammation in Asthma”, Pathobiology, 2002-2003, 70, pp. 297-301.
N.V. Bovin, “Neoglycoconjugates: trade and art”, Biochem. Soc. Symp., 2002, (69), pp. 143-160.
N.V. Bovin, “Polyacrylamide-based blycoconjugates as tools in glycobiology”, Glycoconjugate Journal 15, 1998, pp. 431-446.
T.V. Pochechueva et al., “P-Selectin Blocking Potency of Multimeric Tyrosine Sulfates In Vtiro and In Vivo”, Bioorganic & Medicinal Chemistry Letters 13(10), 2003, pp. 1709-1712.
G. Weitz-Schmidt et al., “An E-Selectin Binding Assay Based on a Polyacrylamide-Type Glycoconjugate”, Analytical Biochemistry 238, 1996, pp. 184-190.
T. Nomoto et al., “Preparation of hydroxybenzamide derivatives as prevention and treatment agents for bone diseases”, Chemical Abstracts + Indexes, American Chemical Society, vol. 13, No. 125, Sep. 23, 1996, XP002047512.
C.C.M. Appledoorn et al., “Rational Optimization of a Short Human P-selectin-binding Peptide Leads to Nanomolar Affinity Antagonists”, Journal of Biological Chemistry, vol. 278, No. 12, Mar. 21, 2003, pp. 10201-10207, XP002275710.
R. Yamazaki et al., “Diarylheptanoids suppress expression of leukocyte adhesion molecules on human vascular endothelial cells”, European Journal of Pharmacology, vol. 404, No. 3, Sep. 22, 2000, pp. 375-385, XP009062460.
C.C.M. Appeldoorn et al., “Gallic Acid Antagonizes P-Selectin-Mediated Platelet-Leukocyte Interactions, Implications for the French Paradox”,CirculationJan. 4/11, 2005, 111, pp. 106-112.
N. Kaila et al., “Quinic Acid Derivatives as Sialyl Lewisx-Mimicking Selectin Inhibitors: Design, Synthesis, and Crystal Structure in Complex with E-Selectin”, J. Med. Chem. 2005, 48, pp. 4346-4357.
D.H. Slee et al., “Development of Potent Non-Carbohydrate Imidazole-Based Small Molecule Selectin Inhibitors with Antiinflammatory Activity”, J. Med. Chem. 2001, 44, pp. 2094-2107.
P.T. Mannisto et al., “Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT Inhibitors”, Pharmacological Reviews, The American Society for Pharmacology and Experimental Therapeutics, 1999, vol. 51, No. 4, pp. 593-628.
J. Axelrod et al., “Enzymatic O-Methylation of Epinephrine and Other Catechols”, J. Biol. Chem., 1958, 223(3), pp. 702-705.
N. Haramaki et al., “Role of Ascorbate in Protection by Nitecapone Against Cardiac Ischemia—Reperfusion Injury”, Biochemical Pharmacology, vol. 50, No. 6, pp. 839-843, 1995.
E. Nissinen et al., “The COMT inhibitor, entacapone, reduces levedopa-induced elevations in plasma homocysteine in healthy adult rats”, J. Neural. Transm., 2005, 112, pp. 1213-1221.
Y.J. Suzuki et al., “Antioxidant Properties of Nitecapone (OR-462)”, Free Radical Biology & Medicine, 1992, vol. 13, pp. 517-525.
L. Marcocci et al., “Nitecapone: A Nitric Oxide Radical Scaventer”, vol. 34, No. 3, Oct. 19

Affiliated with

Also associated with

Rating

Aromatic compounds and their use in medical applications does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aromatic compounds and their use in medical applications, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aromatic compounds and their use in medical applications will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2694314